Concert Pharmaceuticals Inc
NASDAQ:CNCE
Concert Pharmaceuticals Inc
PP&E Gross
Concert Pharmaceuticals Inc
PP&E Gross Peer Comparison
Competitive PP&E Gross Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Concert Pharmaceuticals Inc
NASDAQ:CNCE
|
PP&E Gross
$13.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Gross
$5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Concert Pharmaceuticals Inc's PP&E Gross?
PP&E Gross
13.8m
USD
Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's PP&E Gross amounts to 13.8m USD.
What is Concert Pharmaceuticals Inc's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
44%
Over the last year, the PP&E Gross growth was -10%. The average annual PP&E Gross growth rates for Concert Pharmaceuticals Inc have been 16% over the past three years , 44% over the past five years .